Last reviewed · How we verify
Enhertu
At a glance
| Generic name | Enhertu |
|---|---|
| Sponsor | Washington D.C. Veterans Affairs Medical Center |
| Target | DNA topoisomerase 1, Receptor tyrosine-protein kinase erbB-2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Advanced HER2positive gastric or gastroesophageal junction (GEJ) adenocarcinoma
- Metastatic human epidermal growth factor 2 positive carcinoma of breast
Common side effects
- Decreased white blood cell count
- Decreased hemoglobin
- Decreased neutrophil count
- Nausea
- Increased alanine aminotransferase
- Diarrhea
- Increased aspartate aminotransferase
- Decreased lymphocyte count
- Decreased platelet count
- Increased blood alkaline phosphatase
- Decreased blood potassium
- Fatigue
Serious adverse events
- Diarrhea
- Pneumonia
- Febrile neutropenia
- Hypokalemia
Key clinical trials
- Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (PHASE1)
- Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer (PHASE1)
- Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer (PHASE1)
- Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene (PHASE1)
- Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation (PHASE1, PHASE2)
- Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma (PHASE2)
- A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) (PHASE3)
- Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Enhertu CI brief — competitive landscape report
- Enhertu updates RSS · CI watch RSS
- Washington D.C. Veterans Affairs Medical Center portfolio CI